



AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference

November 19, 2020

MASON, Ohio--(BUSINESS WIRE)--Nov. 19, 2020-- [AtriCure, Inc. \(Nasdaq: ATRC\)](#), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference.

Conference Dates: Tuesday, December 1 to Thursday December 3, 2020

A link to the fireside chat presentation will be available on the "Investors" section of the Company's website at <https://ir.atricure.com>.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter [@AtriCure](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201119005147/en/): <https://www.businesswire.com/news/home/20201119005147/en/>

Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com

Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
lynn@gilmartinir.com

Source: AtriCure, Inc.